Table 1.

Demographics, treatment profiles, and disease activity at enrollment for patients with multidomain vs single-domain PsA disease presentations.

CharacteristicaAll Patients With PsA, N = 2315Biologic Initiators, N = 334
Single Domainb, n = 617Multidomain, n = 1698P*Single Domainb, n = 45Multidomain, n = 289P*
Age, yrs, mean (SD) [n]54.5 (12.9) [607]53.5 (13.2) [1678]0.2052.5 (12.7) [45]51.5 (13.2) [289]0.65
Female, n/N (%)314/610 (51.5)907/1689 (53.7)0.3521/44 (47.7)151/289 (52.2)0.58
Race, n (%)n = 596n = 16550.04n = 43n = 2850.34
        White572 (96.0)1548 (93.5)42 (97.7)256 (89.8)
        Black4 (0.7)9 (0.5)0 (0.0)4 (1.4)
        Other20 (3.4)98 (5.9)1 (2.3)25 (8.8)
BMI, mean (SD) [n], kg/m231.3 (7.6) [600]32.0 (7.4) [1658]< 0.0133.6 (11.9) [45]31.4 (7.3) [287]0.69
Symptom duration, yrs, mean (SD) [n]11.0 (9.7) [594]11.3 (10.7) [1651]0.517.3 (9.0) [44]9.1 (9.9) [286]0.12
Disease duration, yrs, mean (SD) [n]8.5 (8.1) [598]7.7 (8.8) [1662]< 0.016.1 (8.9) [44]6.0 (7.5) [285]0.59
History of psoriasis, n (%)520 (84.3)1537 (90.5)< 0.0133 (73.3)247 (85.5)0.04
History of nail psoriasis, n (%)81 (13.1)602 (35.5)< 0.014 (8.9)85 (29.4)< 0.01
History of comorbidities, n (%)
        Hypertension223 (36.1)679 (40.0)0.0917 (37.8)107 (37.0)0.92
        Hyperlipidemia137 (22.2)433 (25.5)0.108 (17.8)68 (23.5)0.39
        Metabolic syndrome91 (14.7)282 (16.6)0.284 (8.9)44 (15.2)0.26
        Diabetes mellitus93 (15.1)252 (14.8)0.894 (8.9)37 (12.8)0.46
        Cardiovascular disease70 (11.3)205 (16.5)0.631 (2.2)32 (11.1)0.10
        Depression57 (9.2)280 (16.5)< 0.012 (4.4)52 (18.0)0.02
        Any cancer (excluding NMSC)36 (5.8)138 (8.1)0.063 (6.7)21 (7.3)1.00
        Serious infections34 (5.5)99 (5.8)0.773 (6.7)16 (5.5)0.73
        Fibromyalgia23 (3.7)114 (6.7)< 0.01020 (6.9)0.09
        Anxiety12 (1.9)65 (3.8)0.032 (4.4)18 (6.2)1.00
        Uveitis5 (0.8)16 (0.9)0.0707 (2.4)0.60
        Crohn disease4 (0.6)19 (1.1)0.311 (2.2)5 (1.7)0.58
        Ulcerative colitis4 (0.6)16 (0.9)0.5001 (0.3)1.00
History of biologic use, n (%)151 (24.5)561 (33.0)< 0.0122 (48.9)154 (53.3)0.58
History of csDMARD use, n (%)151 (24.5)478 (28.2)0.0812 (26.7)112 (38.8)0.12
History of prednisone use, n (%)83 (13.5)230 (13.5)0.9510 (22.2)60 (20.8)0.82
Current biologic use, n (%)378 (61.3)980 (57.7)0.1345 (100.0)289 (100.0)
Current csDMARD use, n (%)339 (54.9)859 (50.6)0.0624 (53.3)104 (36.0)0.03
Current prednisone use, n (%)42 (6.8)122 (7.2)0.759 (20.0)30 (10.4)0.06
  • a All values were calculated based on available data. For continuous variables, [n] represents the number of patients with data available.

  • b Single-domain disease presentations for PsA overall (N = 617) included skin disease (53.8%), peripheral arthritis (29.0%), nail psoriasis (10.9%), axial disease (3.4%), enthesitis (1.8%), and dactylitis (1.1%). Single-domain disease presentations for biologic initiators (N = 45) included peripheral arthritis (46.7%), skin disease (35.6%), axial disease (6.7%), nail psoriasis (4.4%), enthesitis (4.4%), and dactylitis (2.2%).

  • *Wilcoxon rank-sum test or t-test for continuous variables and chi-square or Fisher exact test for categorical variables. csDMARD: conventional synthetic disease-modifying antirheumatic drug; NMSC: nonmelanoma skin cancer; PsA: psoriatic arthritis.